Peer-reviewed veterinary case report
Safety of compounded L-asparaginase for treating lymphoma in dogs
By Thiman, J et al.·Published in Journal of veterinary pharmacology and therapeutics·2016·Department of Small Animal Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prospective evaluation of the safety of compounded bulk material L-asparaginase in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma were treated with a new compounded version of L-asparaginase, a medication used to fight cancer, to see how safe and effective it was compared to the previously used version, Elspar. The dogs received the treatment along with corticosteroids, and the results showed that 80% of them responded positively, with some achieving complete remission. Importantly, no serious side effects were linked to the new compounded L-asparaginase, making it a promising option for treating lymphoma in dogs.
People also search for: dog lymphoma treatment · L-asparaginase for dogs · side effects of cancer treatment in dogs
Abstract
Use of compounded L-asparaginase became routine in veterinary oncology when manufacturing of Elsparwas discontinued in 2012. The objective of this study was to evaluate the safety of compounded L-asparaginase (CLASP, KRS Global Biotechnology, Boca Raton, FL, USA) in comparison with Elspar(Lundbeck LLC, Deerfield, IL, USA). In addition, we documented the response to CLASP in combination with a corticosteroid in this population of dogs with lymphoma. Dogs were prospectively treated with 10 000 IU/mCLASP or Elsparsubcutaneously. Corticosteroids were administered concurrently. Adverse events (AE) were assessed according to the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events v1.1 (VCOG-CTCAE). Response was recorded. Seventy-three dogs received 75 treatments (CLASP, n = 47; Elspar, n = 28). No AE were attributed to CLASP. Grade I and II AE probably or possibly related to treatment were observed following two Elspartreatments. The overall response rate to the combination of CLASP and a corticosteroid was 80% (24% CR and 56% PR). In combination with a steroid, the compounded L-asparaginase evaluated in this study is safe and demonstrates activity against canine lymphoma. In the face of the discontinuation of Elspar, veterinarians should seek compounded LASP products that have been tested for activity, purity, and sterility.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27086733/